Area of Technology:Life Sciences
Title of the Innovation: A Dual Action (Osteogenic and Anti- resorptive) Combination Oral Therapy for Post-menopausal Osteoporosis (PMO)
Brief About Innovation
Brief: Two clinically used drugs (both generic) proposed to be used in repurposing mode in combination; D678 as a pure osteogenic and D10 as an anti-resorptive (remodelling suppressor) agent. Route of administration for this combo is oral, both are generic (non-antibiotic/non-infectious) and has repetitive mode of use in humans. Dose of D678 is less than human dose for rats/rabbits and D10 is similar to human dose.
Beta Version
Copyright © 2023. NRDC - All Rights Reserved
Designed and Developed by Maxtra Technologies.
